Michael J. Rider, Global General Counsel and Secretary of ResMed Inc, filed a Form 4 on October 26, 2026, disclosing a sale of 400 shares of ResMed common stock on October 23, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Michael J. Rider, identified in the filing as Global General Counsel and Secretary of ResMed Inc (NYSE:RMD).
  • Transaction: 400 shares of ResMed Common Stock disposed of (transaction code S) on October 23, 2026.
  • Sale price: $255 per share, as reported in the filing.
  • Remaining ownership: 12,318 shares of ResMed Common Stock held directly following the transaction.
  • 10b5-1 plan: The sale was conducted under a Rule 10b5-1 plan adopted February 28, 2025, according to the filing's footnote.

Rider's October 2026 Share Sale Under 10b5-1 Plan

According to the Form 4 filed with the SEC on October 26, 2026, Michael J. Rider, who serves as Global General Counsel and Secretary of ResMed Inc, sold 400 shares of ResMed Common Stock on October 23, 2026, at a price of $255 per share. The filing indicates the transaction was a disposition (code S) of directly held shares.

The filing notes that the transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025. Rule 10b5-1 plans allow corporate insiders to set up pre-scheduled trading arrangements at a time when they are not in possession of material non-public information. The filing's checkbox confirms the transaction "was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."

Following the reported sale, Rider's direct beneficial ownership of ResMed Common Stock stands at 12,318 shares, as disclosed in the filing. No derivative securities transactions were reported in Table II of the form. Rider's address of record is listed as 9001 Spectrum Center Blvd, San Diego, California 92123.

What Was Disclosed

The filing discloses a single sale of 400 shares of ResMed Common Stock by Global General Counsel Michael J. Rider at $255 per share on October 23, 2026, executed under a Rule 10b5-1 plan adopted February 28, 2025, leaving him with 12,318 directly held shares.